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Management of arteriovenous malformations: A
multidisciplinary approach
Byung-Boong Lee, MD, PhD, FACS, Y. S. Do, MD, Wayne Yakes, MD, D. I. Kim, MD, Raul Mattassi,
MD, and W. S. Hyon, MD, Seoul, Korea
Background: Management of arteriovenous malformations (AVMs) remains challenging because of their unpredictable
behavior and high recurrence rate. A multidisciplinary approach based on a new classification scheme and improved
diagnostic techniques may improve their management. The purpose of this study was to review our experience with
combined embolotherapy, sclerotherapy (embolo/sclerotherapy), and surgical procedures to manage AVMs.
Methods: A total of 797 patients with congenital vascular malformations (January 1995 through December 2001) was
investigated with noninvasive studies. Once an AVM was diagnosed, all underwent angiographic confirmation as a
roadmap for treatment. Embolo/sclerotherapy and surgical procedures were instituted by the multidisciplinary team
with periodic follow-up per protocol. Seventy-six patients with AVMs were reviewed retrospectively to assess the
diagnosis and management by a multidisciplinary approach.
Results: Seventy-six (9.5% of all CVM) patients had AVMs, mostly infiltrating, extratruncular form (61/76). Embolo/
sclerotherapy with various combinations of absolute ethanol, N-butyl cyanoacrylate (NBCA), contour particles, and coils
were used in 48 patients. Sixteen patients with surgically accessible localized lesions completed preoperative embolism and
sclerotherapy through 24 sessions, with subsequent surgical excision with minimal morbidity. Interim results were
excellent, with no evidence of recurrence in all 16 patients with a mean follow-up of 24 months. Thirty-two patients with
surgically inaccessible lesions (infiltrating) were treated with embolism and sclerotherapy alone. There were nine failures
in a total of 171 sessions. Interim results with a mean of 19 months’ follow-up of embolism and sclerotherapy alone were
excellent in the majority (25/32) and good to fair among the rest (7/32). However, 31 complications, mostly minor
(27/31), occurred in 30 sessions. Four major complications occurred, including facial nerve palsy, pulmonary embolism,
deep vein thrombosis, and massive necrosis of an ear cartilage.
Conclusions: Diagnosis and management of AVMs by a multidisciplinary approach that integrates surgical therapy with
embolism and sclerotherapy appears to improve the results and management with limited morbidity and no recurrence
during early follow-up. (J Vasc Surg 2004;39:590-600.)
Congenital vascular malformations (CVMs), including
arteriovenous malformations (AVMs),1-3 remain an
enigma despite efforts during the last century to improve
their care. They have a wide range of clinical presentation
and an unpredictable course. Complicated anatomic,
pathologic, physiologic, embryonic and hemodynamic
characteristics must be evaluated. Previous classification of
CVMs has created confusion in proper diagnosis. High
morbidity has been related to both surgical and nonsurgical
treatments. There has been an associated high recurrence
rate. Among CVMs, AVMs have been particularly confus-
ing because of their unpredictable nature.4-6
AVMs behave aggressively as a primitive type of CVM
because the majority belong to the extratruncular form as
the residual remnants of a developmental arrest in the early
stage of embryonic life. They have a tendency to progress
with a more destructive potency. The primary effect on the
surrounding tissues is by the lesion itself, with compression
and erosion. Secondary hemodynamic effects include a
potential arterial steal phenomenon. The heart can be
affected by high-output cardiac failure. Peripheral tissues
can be affected in a wide range of changes from distal
ischemia to gangrene, venous stasis dermatitis, and ulcer or
gangrene caused by venous hypertension.2,7-10 AVM, es-
pecially its infiltrating extratruncular form, has a high recur-
rence rate because of its origin from the mesenchymal cells
at an early stage of embryogenesis.11 It retains the evolu-
tional potential to grow, which is often represented clini-
cally as a recurrence.12,13 Its behavior, therefore, is totally
unpredictable, often responding to various stimulations
such as injury or surgical intervention, as well as a systemic
hormone effect. The result can be explosive growth. Im-
proper treatment often stimulates dormant AVM to grow
rapidly, making the condition worse. This recurrence and
unbridled growth are the trademarks of AVM.
Complete eradication of the nidus of an AVM is the
only potential “cure.” But this, however, is often difficult if
not impossible.14 Radical resection to remove the lesion
completely, such as the Malan operation, has been de-
scribed as “demolishing surgery.”6 It is often accompanied
by excessive blood loss in addition to serious complications.
Thus, incomplete removal of the AVM is a frequent result
of attempts to avoid the high morbidity associated with
total excision. Adjuvant therapy in the past has included
ligation or embolization of arteries supplying the AVM.
This approach, however, was based on a poor understand-
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ing of the complicated nature of AVM as an embryonal
remnant.15,16,17
New diagnostic technology, including less invasive im-
aging, has aided the differential diagnosis of CVM to
provide a more precise diagnosis of AVM developed in
different stages of embryogenesis. Contemporary diagno-
sis,18,19 based on the Hamburg classification,20,21 provides
an opportunity for implementation of the new concept of a
multidisciplinary team approach16,17 for managing AVM.
This approach is based on a new classification scheme20
(Table I) and diagnostic technology (Table II). 18
Embolo/sclerotherapy is a new therapeutic modality
that is accepted as independent therapy, especially for sur-
gically inaccessible lesions.2-24 It has also been imple-
mented as preoperative or postoperative adjunct therapy. It
has helped improve surgical results and to expand the role
of surgical therapy.16,17
The purpose of this study was to conduct a retrospec-
tive analysis of the clinical results of a contemporary man-
agement program for AVM that was based on a multidisci-
plinary approach with full integration of embolo/
sclerotherapy and surgical intervention.
PATIENTS AND METHODS
Among 797 patients with CVMs investigated at Sam-
sung Medical Center, Seoul, Korea, from January 1995
through December 2001, 76 patients (9.5%) were con-
firmed to have AVMs (Fig 1). The AVMs were mostly
diffuse infiltrating extratruncular AVMs accompanied by
a macro-arteriovenous (AV) shunting nidus (61/76).
The majority (23) were in the head and neck region, and
the second-largest portion were in the upper extremity
(17). Multiple site involvement was common (13). AVM
patients were evaluated by the new classifications.25,26
Table III. Treatment indications for AVMs*
Absolute indications
Hemorrhage, major or recurrent minor (16/48)
Gangrene or ulcer of arterial, venous or combined origin (18/
48)
Ischemic complication of acute and/or chronic arterial
insufficiency (26/48)
Progressive venous complication of chronic venous
insufficiency with venous hypertension (30/48)
High-output cardiac failure—clinical and/or laboratory (8/
48)
Lesions located at life-threatening vital areas that compromise
seeing, hearing, eating or breathing (13/48)
Relative indications
Various symptoms and signs affecting the quality of life;
disabling pain and/or functional impairment (43/48)
Lesions with potentially high risk of complications (eg,
hemarthrosis) and/or limb-threatening location (34/48)
Vascular-bone syndrome with limb length discrepancy (21/
48)
Cosmetically severe deformity with/without functional
disability (28/48)
*Demographic data of 48 patients described in the study are included.
Table I. Hamburg classification of congenital vascular
malformation: 1988 with modification
Species* Anatomical form†
Predominantly arterial defects Truncular forms
Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
Predominantly venous defects Truncular forms
Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
Predominantly AV shunting
defects
Truncular forms
Deep AV fistula
Superficial AV fistula
Extratruncular forms
Infiltrating
Limited
Combined vascular defects Truncular forms
Arterial and venous
Hemolymphatic
Extratruncular forms
Infiltrating hemolymphatic
Limited hemolymphatic
Predominantly lymphatic
defects
Truncular forms
Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
AV, Arteriovenous.
*Based on the consensus of the International Society for the Surgery of
Vascular Anomalies through the internatoinal workshop on congenital
vascular malformation held in Hamburg, Germany, 1988: Capillary malfor-
mation was not included.
†Based on the embryologic stage at which the developmental arrest has
occurred.
Table II. Diagnosis of AVMs
I. Non- to less-invasive study: essential for the baseline
evaluation
Duplex scan (arterial and venous)
Whole body blood pool scan
Transarterial lung perfusion scan
MRI with T1 & T2 image
CT scan with angio-contrast enhancement*
Lymphoscintigraphy*
Ultrasonographic lymphangiography
MR lymphangiography*
Volumetry*
Air plethysmography*
II. Invasive study: essential for the confirmation and proper
disposition of AVMs as a road-map for treatment
Selective & superselective arteriography
Direct puncture arteriography
Standard and/or direct puncture phlebography
Direct puncture lymphangiography*
AVM, Arteriovenous malformation; MRI, magnetic resonance imaging; CT,
computed tomography.
*Optional.
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Various combinations of the noninvasive studies based
on new diagnostic technologies27,28 were implemented
per protocol (Table II). When the AVM was diagnosed,
further review was made by the multidisciplinary
team.16,17 Treatment was approved by consensus (Table
III). All AVMs had angiographic evaluation to deter-
mine further detailed anatomic and hemodynamic infor-
mation of the AVM lesion.
Transarterial lung perfusion scan (TLPS) was added as
a new, less invasive test to measure the extent of arterio-
venous shunting of the AVM. The TLPS was implemented
not only for the initial diagnosis but also for follow-up
assessment of the treated and untreated lesions. TLPS has
been used mostly for AVMs located within the extremity
because of the technical limitation of safe access through
the femoral or axillary artery for injection. This scinti-
graphic study used 99m technetium–labeled microsphere
albumin. It provided quantitative assessment of the shunt-
ing volume to the lung through the nidus of the AVM to
calculate the shunting percentage.
Whole-body blood pool scans (WBBPSs) were also
included as one of the basic noninvasive tests for AVMs.
They used 99m-technetium–tagged erythrocytes to detect
abnormal blood pooling through the body. The quantita-
tive assessment was made for the reduction of relative
amount, size, and intensity of the blood pooling on the
scintigram by the treatment. It was calculated as follows:
Reduction percentage 
1 
Posttreatment ratio of region of interest/whole body
Baseline ratio at the region of interest
Duplex sonography and magnetic resonance imaging
were also included as essential noninvasive tests.
Of the 76 patients with AVMs, 48 patients (extratrun-
cular form, 42 and truncular form, 6; male, 22 and female,
26; age range, 6 to 62 years) were selected for treatment.
They were selected for treatment based on a minimum of
two indications, described in Table III. The majority of
patients had various symptoms affecting their quality of life
(43/48), with frequent indications being venous compli-
cations (30/48) and potential high risk of complications
because of the location (34/48).
Selection of surgical intervention or embolo/sclero-
therapy, either as independent therapy or as adjunct ther-
apy before surgical therapy, depended on the type, loca-
tion, and extent of the lesions. Anticipation of associated
morbidity after the therapy was always considered. Em-
bolo/sclerotherapy alone using various embolo/sclero-
sants29-34 was implemented mostly to manage the surgi-
cally inaccessible AVMs or those that were considered to be
at high surgical risk. Surgical procedures were preferred for
all accessible AVMs with acceptable risk to attempt a cure.
However, a combined approach with preoperative em-
bolo/sclerotherapy17,35,37 was implemented for surgically
accessible lesions whenever feasible to reduce surgical mor-
bidity. Full integration of various surgical and nonsurgical
treatment modalities was implemented for complex AVMs
through the multidisciplinary approach.18
Extratruncal (ET) AVMs, which consist mostly of non-
fistulous lesions with a treatable nidus, were assigned for
treatment with ethanol as sole therapy when the lesion was
not surgically amenable because of diffuse infiltration. Sur-
gically amenable, limited (localized) ET AVMs were
treated with preoperative embolo/sclerotherapy and sub-
sequent surgical therapy. Truncular (T) AVMs, which were
mostly fistulous lesions without an adequately treatable
Fig 1. Congenital vascular malformation based on the Hamburg classification for 797 patients registered at CVM
Clinic, Vascular Center, Samsung Medical Center (January 1995 through December 2001): 446 females and 351
males; mean age 22.1 years (range, 14 days to 81 years). **Due to various factors including young age, final diagnosis
was temporarily deferred until conclusive diagnostic procedures could be included. Unclassified malformations are,
however, mostly venous malformations clinically and subsequently confirmed as venous malformations after lymphatic
malformations, etc, were properly ruled out. In addition to these deferred diagnostic cases, there were truly
unclassifiable malformations from hemangioma as well as capillary malformations clinically and/or histopathologically.
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direct connection between an artery and a vein, were as-
signed to surgical excision combined with preoperative
embolo/sclerotherapy when the lesion was surgically ame-
nable as a superficial fistula. Independent embolo/sclero-
therapy was assigned to the surgically inaccessible, deep-
seated fistula, which was the usual experience.
As embolo/scleroagents, absolute to 80% ethanol, N-
butyl cyanoacrylate (NBCA), various types of coils, and/or
contour particles such as ivalon were used in various com-
binations, simultaneously or in stages, depending upon the
location, severity, and extent of the AVM. Absolute to 80%
ethanol was used as the main agent in the surgically inac-
cessible lesions. It was given via transarterial, transvenous,
or direct puncture injection. This depended on the ana-
tomic or hemodynamic status of the individual AVM.
NBCA glue was used mainly for the surgically excisable
lesions as preoperative embolo/sclerotherapy to reduce the
morbidity during the subsequent surgical therapy.18 We
did not use it as permanent agent to control AVM because
there is a lack of convincing evidence that this induces
permanent damage to the endothelial cells. The treatment
response as well as interim or final results were assessed
periodically by the multidisciplinary team per protocol.22,24
Clinical assessment was based on the subjective im-
provement of clinical symptoms on a scale of 0 to 10 and on
objective evidence of improved clinical signs such as a
healed ulcer, cessation of bleeding, reduction of swelling,
or improved range of motion on a scale of 0 to 5, to classify
the response as “excellent,” “good,” or “fair.”22,24 Labo-
ratory assessment was based on various combinations of
noninvasive to less invasive tests, such as duplex scan,
WBBPS, TLPS, magnetic resonance imaging (MRI), espe-
cially the interim assessment during multisession therapy.
However, the angiographic finding was the gold standard
for the ultimate assessment of the treatment response. At
the conclusion of each treatment as well as at the comple-
tion of multisession therapy, “excellent” was the rating for
complete control (disappearance), “good” was the rating
for near-complete control with negligible evidence of re-
sidual lesions, and “fair” was the rating for substantial
control with significant residual lesion that warranted fur-
ther close observation. Similar criteria were applied to the
various noninvasive to less-invasive tests for the treatment
result assessment. For example, the duplex scan evaluation
was based on the hemodynamic status along the lesion.
Complete cessation of the hemodynamic activity at the
treated nidus was “excellent.” Near-complete cessation,
but with some suspicion along the feeding artery and
draining veins, was “good.” Drastic reduction, but with
substantial evidence of the residual activity of the treated
nidus, was “fair.” For WBBPS, TLPS, and MRI, the same
criteria for arteriographic and duplex interpretation of the
treatment response were implemented with some modifi-
cation.
Periodic follow-up evaluation of the treatment results
was made based on the duplex scan, WBBPS, TLPS, or
MRI in the majority, especially during the multisession
therapy. Proper combination of these noninvasive to less
invasive tests was adequate to replace most of the role
classically played by angiography, not only for the interim
treatment response assessment but also for the follow-up
assessment of the AVM. However, arteriography has re-
mained the ultimate gold standard for AVM management.
It has been included especially for the final confirmation of
the treatment results and subsequent follow-up biannually,
as routine protocol for AVM follow-up.
RESULTS
Sixteen (extratruncular, 14; truncular, 2) of 48 patients
with AVMs were selected for preoperative embolo/sclero-
therapy. These patients had surgically accessible lesions
with localized, noninfiltrating AVMs. Fifteen patients had
multiple sessions of preoperative embolo/sclerotherapy to
facilitate subsequent surgical excision. The sessions used
mainly NBCA glue with or without additional ethanol
(13/16 patients; NBCA glue only, 9; NBCA glue and
ethanol, 4; ethanol only, 2; and ethanol and ivalon, l). All
16 patients had subsequent surgical excision within 2 to 4
weeks after the embolo/sclerotherapy. This reduced mor-
bidity, through selective excision of the lesion only. There
was minimal blood loss averaging 200 mL, in contrast to
massive blood loss with the more conventional surgical
therapy alone (Fig 2). One patient had a pulmonary embo-
lism after the use of NBCA glue. All 16 patients had
excellent interim results with no evidence of recurrence
during a follow-up averaging 24.3 months; these results
were confirmed angiographically.
Thirty-two patients (extratruncal, 28; truncal, 4) with
surgically inaccessible lesions, mostly diffuse infiltrating
AVMs (buttock, thigh, and calf muscles), were indicated
for the independent embolo/sclerotherapy. There were
171 sessions with 9 failures. Figures 3 and 4 identify the
combinations of agents. Ethanol was combined with coils,
glues, or contour particles (158/162 of the successful
sessions), and ethanol was used alone in 132 sessions. The
majority (25/32 patients) were considered to have an
excellent result during follow-up averaging 13.6 months.
There was good to fair control of the activity of the nidus
among the remaining seven. All had angiographic follow-
up. There was no evidence of recurrence during a follow-up
of 19.2 after the study protocol. There were, however, 31
complications with the majority, 27 being minor involving
the skin. This usually followed treatment using ethanol.
Three of the 4 major complications developed after ethanol
therapy: 1 transient facial nerve palsy, 1 deep vein throm-
bosis, and 1 massive ear cartilage necrosis. There was 1
pulmonary embolism after the NBCA glue embolotherapy
to a truncal AVM of the fistulous type. These major com-
plications developed in high-flow conditions, whereas the
majority of minor complications developed among the
extratruncular AVMs. One patient with a high-flow AVM
fistula involving bone had cessation of treatment despite
what was considered to be good progress of the therapy.
Subsequently, the patient required forearm amputation to
arrest recurrent massive bleeding and high-output cardiac
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failure as a lifesaving procedure. Unfortunately, the patient
eventually committed suicide.
DISCUSSION
Although improved diagnoses based on advanced tech-
nology provide adequate information for appropriate treat-
ment, AVM remains the most difficult type of CVM. There
is a higher risk of complications and morbidity with AVM.
Despite our efforts, complications associated with AVM
treatment remain higher than we desire.
Clinically, it is difficult to select the optimal treatment
to enhance long-term success in managing AVMs. Surgical
excision offers the best opportunity for “cure.” However,
diffuse excision of infiltrating AVMs of the extratruncular
form can be associated with significant morbidity as well as
with failure of attempted cure. Embolo/sclerotherapy can
Fig 2. Preoperative embolotherapy with N-butyl cyanoacrylate (NBCA), combined with surgical excision of a
recurrent AVM lesion. A, Clinical appearance of painful tender swelling along the right flank after initially successful coil
embolotherapy, done elsewhere. B, Plain roentgenogram finding of the scattered coils that were previously used to shut
off the feeding artery only. C, MRI finding of the AVM lesion, confirmed as a diffuse infiltrating type of the
extratruncular form, mostly limited to the soft tissue. D, Angiographic finding of the recurred AVM lesion with
multiple new or old feeding arteries.
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be successful as a second choice in treating AVMs. We
adopted absolute ethanol reluctantly as a major scleroagent
despite the high complication rate reported elsewhere.22,24
Until a better agent for sclerotherapy is identified, this
approach has been associated with the fewest recurrences of
AVMs.
Sclerotherapy alone using absolute ethanol to treat
surgically inaccessible AVMs is associated with complica-
tions; however, major complications were reasonably low in
our series (in 4/186 sessions, complications arose in 4/48
patients). We do not recommend absolute ethanol in AVM
treatment unless there is a specialized team approach, such
as in our referral center. We recognize that serious consid-
eration of significant risk continues to be the challenge of
many AVMs. For surgically inaccessible AVMs, we used
embolo/sclerotherapy.
Recurrence remains a challenge, particularly with
extratruncal AVMs. Nevertheless, inadequately treated
lesions represent greater problems than the evolutional
potential for recurrence. Because of this, our clinical
approach for AVM concentrates on the hemodynamic
aspects of the AVM. The high-flow status of the fistulous
type of truncal AVM makes treatment extremely diffi-
cult, if not impossible, without additional morbidity
(deep vein thrombosis and pulmonary embolism). Tem-
porary control of inflow or outflow of the lesion with
balloon catheters has helped implement control of the
high-flow status. There is less risk for subsequent therapy
with this approach. Ethanol sclerotherapy to high-flow
fistulous lesions is usually contraindicated because of the
high risk of early wash into the systemic circulation.
Fig 2 (continued). E, Radiographic finding of the NBCA glue-filled AVM lesion after preoperative embolotherapy for
the subsequent surgical therapy. F, Gross finding of the surgical specimen containing glue-filled vessels. G, Clinical
result of well-healed surgical wound after the en bloc resection of the recurred infiltrating lesion at the flank with
minimum blood loss by the preoperative glue embolization.
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Fig 3. Isolated ethanol sclerotherapy of an AVM. A, Clinical appearance of the AVM lesion affecting the hip region
with progressive symptoms. B, WBBPS finding of the extent of hemodynamically aggressive AVM lesion along the right
hip; note the enormous size of right iliac artery equivalent to the size of abdominal aorta. C, MRI finding of the AVM
lesion, confirmed as infiltrating type of the extratruncular form, affecting entire right hip soft tissue and muscles, and so
on. D, TLPS finding of the AV shunting status of the lesion (pretreatment baseline study).
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NBCA embolotherapy is relatively contraindicated in
this case as well.
The role of NBCA embolotherapy in our clinic is
specific. Its role is limited to adjunct therapy for subsequent
surgery. Our intention is to remove all NBCA glue, to-
gether with the lesion, whenever possible during surgical
excision. NBCA embolotherapy helps control bleeding and
helps provide an excellent local guide for excision. We do
not believe that NBCA can act as a permanent agent to
control a lesion effectively because there is no evidence of
permanent damage to the endothelium.
The fistulous AVM without a treatable nidus was con-
trolled generally through a staged approach, using a new
strategy of coil embolotherapy as a preliminary procedure
to slow down the flow, thus reducing the risk of subsequent
distal thromboembolism. Ethanol or NBCA glue embolo/
sclerotherapy then followed the coil embolotherapy.
Classification of CVM, such as Klippel-Trenaunay and
Parkes-Weber syndromes, has been confusing.6,38,39 A new
classification based on a consensus from the workshop of
the International Society for the Study of Vascular Anomaly
in 1988 has more clinical applicability.37 Anatomic, patho-
logic, and physiologic status of developmental failures in
various stages of embryogenesis are included.12,13 There
has been further modification of the classification of
CVM.20,21 The basis of contemporary diagnosis of CVM
has eliminated the old eponym-based classification.18,38,39
There is clarification between CVM and the true infantile
hemangioma, which is a vascular tumor.40-43 Although
they are related vascular anomalies, these are two indepen-
dent entities. The new classification of CVM has provided
critical support for improved management of AVMs based
on the new diagnostic technology developed for CVM in
general. Various noninvasive to less-invasive tests were
introduced to assess detailed hemodynamic status of
AVM.41 Precise evaluation of AVM has been a result.
WBBPS and TLPS have helped to evaluate the initial lesion
as well as the interim treatment results of AVM during
multisession therapy. Subsequent long-term outcome as-
sessment has also been aided in cases of either treated or
untreated AVMs. TLPS is important in screening for hid-
den micro-AV shunting in AVMs before using invasive
arteriographic evaluation.
Duplex ultrasonography has been of value in assessing
AVMs. It also helps evaluate inflow arteries, outflow veins,
and collateral vessels of the AVM. It is important to assess
the interim results during each session of the multisession
therapy as well as to assess the long-term outcome of the
treated and untreated lesions. MRI is a contemporary gold
standard for assessing the anatomic status of the AVM. It
delineates the lesion as well as the relationship to surround-
ing tissues and organs, including muscle, tendon, nerve,
vessel, and bone. It helps differentiate low-flow and high-
flow status of the CVM in general.
All AVMs are potentially limb threatening and even
life-threatening. An early aggressive approach to all AVMs
is warranted to reduce, if not prevent, the immediate risk of
bleeding as well as the long-term risks of cardiac failure and
gangrene. Ligating the feeding artery to an AVM, as was
done for many years, only leaves the nidus of the lesion
Fig 3 (continued). E, Angiographic finding of the ethanol sclerotherapy directly to the multiple niduses of the
extratruncular form of the AVM lesion, reached by superselective catheterization technique. F, Angiographic finding of
the interim results of the effective control of the niduses by multisession ethanol sclerotherapy, leaving feeding vessels
intact.
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intact. This is followed by more aggressive neovascular
development to make the AVM more of a risk. Aggressive
control of the nidus of the AVM is essential.
Current management of AVMs based on the new con-
cept of multidisciplinary approach11,16,17 can minimize the
morbidity and reduce recurrence. There has been further
Fig 4. “Staged” embolo/sclerotherapy with absolute ethanol and coil, to a recurred AVM. A, Clinical appearance of
left calf swelling with increasing pain, after unsuccessful embolo/sclerotherapy done elsewhere. B, WBBPS finding of
the lesion within the left calf with abnormal blood pool (pretreatment). C, MRI finding to confirm the diffuse
infiltrating type of extratruncular form of AVM within the calf muscles (pretreatment). D, Duplex scan finding of
hemodynamically high-flow status along the feeding artery at the popliteal artery level (pretreatment). E, Arterio-
graphic finding of AVM lesion to confirm the extratruncular form with the nidus (pretreatment).
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expansion of the limited role of embolo/sclerotherapy as
an adjunctive therapy for conventional surgical resection.
This approach has even been helpful in high-risk lesions
with high flow status. Multidirectional use of transarterial,
transvenous, or percutaneous combinations has been help-
ful. There must be a positive balance between subsequent
morbidity and the treatment gains from an aggressive plan.
The importance of careful assessment of the treatment
strategy before the therapy is instituted, based on the ratio of
the benefit versus potential risk, cannot be overempha-
sized.16,17 Amputation should not be excluded as one of
the practical options, especially when the AVM is in an
extremity with total loss of function.
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Fig 4 (continued). F, Angiographic finding of the ethanol sclerotherapy to the nidus of the lesion by transarterial and
transcutaneous (direct puncture) catheterization technique. G, Angiographic finding of the final successful result of
ethanol sclerotherapy combined with coil embolotherapy. H, I, Transarterial lung perfusion scan findings of the AV
shunting status (before and after embolo/sclerotherapy): initial shunting status of 72% range through the AVM nidus
before treatment is successfully lowered to the 1% baseline value to confirm the successful therapy.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 3 Lee et al 599
REFERENCES
1. Belov S. Classification, terminology, and nosology of congenital vascu-
lar defects. In: Belov S, Loose DA, Weber J, editors. Vascular malfor-
mation. Reinbek, Germany: Einhorn-Presse; 1989. p. 25-30.
2. Mulliken JB. Cutaneous vascular anomalies. Semin Vasc Surg 1993;6:
204-18.
3. Rutherford RB. Classification of peripheral congenital vascular malfor-
mations. In: Ernst C, Stanley J, editors. Current therapy in vascular
surgery 3rd ed. St. Louis, Mo: Mosby; 1995. p. 834-8.
4. Szilagyi DE, Smith RF, Elliott JP, Hageman JH. Congenital arterio-
venous anomalies of the limbs. Arch Surg 1976;111:423-9.
5. Malan E. Considerazioni sulle fistole artero-venose congenite degli arti.
Boll Soc Riem Chir 1954;9:196-202.
6. Malan E. Vascular malformations (angiodysplasias). Milan, Italy: Carlo
Erba; 1974. p. 17-31.
7. Malan E. Hemodynamic phenomena in congenital arteriovenous fistu-
lae. In: Malan E, editor. Vascular malformations. Milan, Italy: Carlo
Erba, 1974. p. 38-58.
8. Belov S. Hemodynamic pathogenesis of vascular-bone syndromes in
congenital vascular defects. Int Angiol 1990;9:155-62.
9. Weber J, Ritter H. Strategies for the radiological angiotherapy for
hyperdynamic A-V malformations. In: Belov St, Loose DA, Weber J,
editors. Vascular malformations. Reinbek, Germany: Einhorn-Presse
Verlag GmbH; 1989. p. 270-4.
10. Hemingway AP, Allison DJ. Cardiac failure secondary to giant systemic
arteriovenous malformations: treatment by embolization. In: Belov St,
Loose DA, Weber J, editors. Vascular malformations. Reinbek, Ger-
many: Einhorn-Presse Verlag GmbH; 1989. p. 275-8.
11. Lee BB. Congenital venous malformation: new look to old problem
with multidisciplinary approach. In: Wang ZG, editor. Vascular surgery
proceedings of the 3rd Congress of Asian Vascular Society. Beijing,
China: International Academic Publishers; 1998. p. 252-4.
12. Bastide G, Lefebvre D. Anatomy and organogenesis and vascular mal-
formations. In: Belov St, Loose DA, Weber J, editors. Vascular
malformations. Reinbek, Germany: Einhorn-Presse Verlag GmbH;
1989. p. 20-2.
13. Woolard HH. The development of the principal arterial stems in the
forelimb of the pig. Contrib Embryol 1922;14:139-54.
14. Fontaine R. Spezielle therapeutische Aspekte gewisser arteriovenoser
Mibbildungen. In: Schoginger RA, editor. Periphere angiodysplasien.
Bern, Switzerland: Huber-Verlag; 1977. p. 197-206.
15. Weber J. Vaso-occlusive angiotherapy (VAT) in congenital vascular
malformations. Semin Vasc Surg 1993;4:279-96.
16. Lee BB. Advanced management of congenital vascular malformations
(CVM). Int Angiol 2002;21:209-13.
17. Lee BB, Bergan JJ. Advanced management of congenital vascular
malformations: a multidisciplinary approach. J Cardiovasc Surg 2002;
10:523-33.
18. Lee BB. Nouvelles donnees diagnostiques et therapeutiques sur les
malformations veineuses congenitales. Angeiologie 1998;50:17-9.
19. Lee BB. What is new in venous disease: new approach to old problem of
venous disease congenital vascular malformation. In: Angelides NS,
editor. Advances in phlebology. Limassol, Cyprus: Hadjigeogiou Print-
ing; 1998. p. 59-64.
20. Belov ST. Classification of congenital vascular defects. Int Angiol
1990;9:141-6.
21. Belov ST. Anatomopathological classification of congenital vascular
defects. Semin Vasc Surg 1993;6:219-24.
22. Lee BB, Kim DI, Huh S, Kim HH, Choo IW, Byun HS, et al. New
experiences with absolute ethanol sclerotherapy in the management of a
complex form of congenital venous malformation. J Vasc Surg 2001;
33:764-72.
23. Huh S, Kim DI, Lee SJ, Park HS, Lee BB, et al. Sclerotherapy with pure
ethanol in congenital vascular malformation. J Korean Vasc Surg Soc
1999;56:731-43.
24. Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced
management of venous malformation (VM) with ethanol sclerotherapy:
mid-term results. J Vasc Surg 2003;37:533-8.
25. Belov S. Anatomopathological classification of congenital vascular de-
fects. Semin Vasc Surg 1993;6:219-24.
26. Belov S. Classification of congenital vascular defects. Int Angiol 1990;
9:141-6.
27. Rutherford RB. Congenital vascular malformations: diagnostic evalua-
tion. Semin Vasc Surg 1993;6:225-32.
28. Yakes WF, Parker SH. Diagnosis and management of vascular anoma-
lies. Interv Rad 1992;1:152-89.
29. Yakes WF, Pevsner PH, Reed MD, Donohu HJ, Ghaed N. Serial
embolizations of an extremity arteriovenous malformation with alcohol
via direct percutaneous puncture. AJR Am J Roentgenol 1986;146:
1038-40.
30. Yakes WF, Luethke JM, Merland JJ, Rak KM, Slater DD, Hollis HW, et
al. Ethanol embolization of arteriovenous fistulas: a primary mode of
therapy. JVIR 1990;1:89-96.
31. Weber J. Embolizing materials and catheter techniques for angiothera-
peutic management of the AVM. In: Belov St, Loose DA, Weber J,
editors. Vascular malformations. Reinbek, Germany: Einhorn-Presse
Verlag GmbH; 1989. p. 252-60.
32. Gianturco C, Anderson JH, Wallace S. Mechanical devices for arterial
occlusion. AJR Am J Roentgenol 1975;124:428-30.
33. Weber JH. Vaso-occlusive angiotherapy (VAT) in congenital vascular
malformations. Semin Vasc Surg 1993;6:279-96.
34. Kim KH, Kim HH, Lee SK, Lee BB. OK-432 intralesional injection
therapy for lymphangioma in children. J Korean Assoc Pediatr Surg
2001;7:142-6.
35. Loose DA, Weber J. Indications and tactics for a combined treatment of
congenital vascular malformations. In: Balas P, editor. Progress is
Angiology. Chapt Miscellanea. Torino, Italy: Minerva Medica; 1991. p.
373-8.
36. Lee BB. Congenital venous malformation: changing concept on the
current diagnosis and management. Asian J Surg 1999;22:152-4.
37. Mattassi R. Experiences in surgical treatment of congenital vascular
malformation: changes in diagnosis and surgical tactics in the view of
new experiences. In: Belov S, Loose DA, Weber J, editors. Vascular
malformations. Reinbek, Germany: Einhorn-Presse Verlag GmbH;
1989. p. 202-5.
38. Leu HJ. Pathomorphology of vascular malformations: analysis of 310
cases. Int Angiol 1990;9:147-55.
39. van der Stricht J. Les syndromes “Type” Klippel et Trenaunay. Phlebo-
logie 1992;45:483-7.
40. Mulliken JB. Cutaneous vascular anomalies. Semin Vasc Surg 1993;6:
204-18.
41. Rutherford RB. Congenital vascular defects and hemangiomas [edito-
rial]. Semin Vasc Surg 1993;6:197-9.
42. Folkman J. Toward a new understanding of vascular proliferative dis-
ease in children. Pediatrics 1984;74:850-6.
43. Mulliken JB, Zetter BR, Folkman J. In vivo characteristics of endothe-
lium from hemangiomas and vascular malformations. Surgery 1982;92:
348-53.
Submitted Feb 28, 2003; accepted Oct 18, 2003.
JOURNAL OF VASCULAR SURGERY
March 2004600 Lee et al
